Dyne Therapeutics

Dyne Therapeutics

Associate Director, Statistical Programming

Waltham, MA · Director

Sponsorship not specified$175k-$204kDetected 8 days ago
PythonData AnalysisData VisualizationStatisticsProject ManagementStakeholder ManagementProcess ImprovementClinical TrialsFDA RegulatorySASAnimal StudiesLeadershipCommunicationCollaborationBiostatistics

About the role

  • Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
  • The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
  • Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Requirements

  • Minimum of 10 years of statistical programming experience within the pharmaceutical, biotechnology, including multi-study experience
  • Strong knowledge and applied experience with CDISC standards (SDTM, ADaM), regulatory submission requirements, and data standards
  • Strong understanding of the clinical development process and cross-functional collaboration with Biostatistics, Data Management and Clinical Development organizations
  • Ability to adapt to changing priorities and contribute to departmental strategy, innovation, and continuous improvement initiatives

Nice to have

  • Bachelor's degree required
  • advanced degree preferred in statistics, biostatistics, computer science, life sciences, or a related field
  • Advanced proficiency in SAS required
  • experience with R, Python preferred.
  • Experience coordinating vendor/FSP statistical programming activities across multiple studies preferred

Skills

  • Coordinate and oversee vendor/FSP statistical programming activities across studies to ensure quality, compliance, and timely delivery

Compensation

  • $175,000 - $204,000 USD

Company info

  • We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease.
  • The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
  • At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.

This listing is sourced directly from Dyne Therapeutics's careers page and normalized into a canonical job model.